$2.29
Price
$530M
Market Cap
—
P/E Ratio
-4.0
Forward P/E
$-0.69
EPS (TTM)
—
Dividend Yield
$180M
Cash
$203M
Total Debt
231M
Shares Out
$0.76
$3.87
52-Week Range
Institutional Ownership of GOSSAMER BIO INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for GOSSAMER BIO INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| No activity found for this stock. | |||||
Insider Trading for GOSSAMER BIO INC
6 Months Insider Sentiment
Buy $0
Sell $0
0
Buys
0
Sells
+0
Net
6
Grants
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 02, 2026 | Bryan Giraudo | COO/CFO | GRANT | 115.8K | — | — |
| Jan 02, 2026 | Caryn Peterson | EVP, Regulatory Affairs | GRANT | 84.5K | — | — |
| Jan 02, 2026 | Hasnain Faheem | President & CEO | GRANT | 280.0K | — | — |
| Jan 02, 2026 | Richard Aranda | Chief Medical Officer | GRANT | 93.8K | — | — |
| Jan 02, 2026 | Robert Paul Smith JR | Chief Commercial Officer | GRANT | 93.8K | — | — |
| Jan 02, 2026 | Waage Christian | EVP, Tech Ops and Admin | GRANT | 84.5K | — | — |